206 studies found for:    "Essential thrombocythemia"
Show Display Options
RSS Create an RSS feed from your search for:
"Essential thrombocythemia"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis;   Polycythemia Vera;   Essential Thrombocythemia
Intervention: Drug: Momelotinib
2 No longer available INC424 for Patients With Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis
Conditions: Myelofibrosis (PMF);   Post Polycythemia Myelofibrosis (PPV MF);   Post-essential Thrombocythemia Myelofibrosis (PET-MF);   Myelofibrosis;   Post Polycythemia Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Intervention: Drug: INC424
3 Unknown  A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Drug: HDAC inhibitor (MK-0683)
4 Completed Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera
Conditions: Essential Thrombocythemia;   Polycythemia Vera
Intervention: Drug: Imetelstat
5 Not yet recruiting Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia
Conditions: MPN;   Essential Thrombocythemia
Interventions: Other: Aspirin therapy interruption;   Other: Usual treatment by aspirin 100 mg/d in the active comparator arm;   Other: No interruption of aspirin in the Observational arm;   Drug: Hydroxyurea treatment (HU)
6 Completed Anagrelide Retard in Essential Thrombocythemia
Condition: Essential Thrombocythemia
Interventions: Drug: Anagrelide retard;   Drug: Thromboreductin
7 Recruiting Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes
Conditions: Polycythemia Vera;   Essential Thrombocythemia;   Myelofibrosis
Intervention:
8 Terminated Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Drug: Momelotinib
9 Completed
Has Results
Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Conditions: Primary Myelofibrosis (PMF);   Post Polycythaemia Myelofibrosis (PPV MF);   Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Intervention: Drug: INC424
10 Recruiting Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
Conditions: High Risk Polycythemia Vera;   High Risk Essential Thrombocythemia
Interventions: Drug: PEGASYS;   Drug: Hydroxyurea;   Drug: Aspirin
11 Recruiting Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Conditions: High Risk Polycythemia Vera;   High Risk Essential Thrombocythemia
Interventions: Drug: PEGASYS;   Drug: Aspirin
12 Completed Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: CYT387
13 Completed Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: Momelotinib
14 Recruiting Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: NS-018
15 Completed Pediatric Disease Registry in Essential Thrombocythaemia (ET)
Condition: Essential Thrombocythemia (ET)
Intervention:
16 Completed Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia;   Essential Thrombocythemia
Intervention: Drug: LY573636-sodium
17 Completed
Has Results
Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia
Condition: Essential Thrombocythemia (ET)
Intervention: Drug: SPD422 (anagrelide hydrochloride)
18 Completed
Has Results
French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia
Condition: Essential Thrombocythemia
Intervention:
19 Completed Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia
Condition: Essential Thrombocythaemia
Interventions: Drug: Anagrelide;   Drug: Hydroxyurea
20 Completed
Has Results
The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET)
Condition: Essential Thrombocythaemia
Intervention: Drug: anagrelide hydrochloride

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years